NCT04627480 is a Phase 4 clinical trial of Fisher Wallace Neurostimulation Device in Insomnia, sponsored by ProofPilot.

Who is sponsoring NCT04627480?

NCT04627480 is sponsored by ProofPilot.

What drugs are being tested in NCT04627480?

Interventions in NCT04627480: Fisher Wallace Neurostimulation Device.

What condition does NCT04627480 study?

NCT04627480 studies Insomnia, Insomnia Chronic, Sleep.

Is NCT04627480 still recruiting?

NCT04627480 is currently active, enrolled. Last updated 14 January 2021.

Last reviewed 2021-01-14 · How we verify

NCT04627480

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial

Active, enrolled Phase 4 Last updated 14 January 2021

What this trial tests

Phase 4 trial testing Fisher Wallace Neurostimulation Device in Insomnia in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 October 2020

Primary endpoint
31 January 2021

21 February 2021

Quick facts

Lead sponsor	ProofPilot
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	200
Start date	1 October 2020
Primary completion	31 January 2021
Estimated completion	21 February 2021
Sites	1 location across United States

Drugs / interventions tested

Fisher Wallace Neurostimulation Device

Conditions studied

Insomnia — all drugs for Insomnia →
Insomnia Chronic — all drugs for Insomnia Chronic →
Sleep — all drugs for Sleep →

Sponsor

ProofPilot

Who can join

21 and older, any sex, with Insomnia or Insomnia Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator Device (CES) for the treatment of insomnia characterized by difficulties with sleep maintenance using a 20-minute treatment right before bedtime.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124
Trends of Decentralized Clinical Trials Using Digital Technology for Decentralization
Sato T, Mizumoto S, Ota M, Shikano M. · · 2022 · DOI 10.2139/ssrn.4243284

Verify or expand the search:

Other recruiting trials for Insomnia

Currently open trials in the same condition.

NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting
NCT07071324 — CF Wellness Program · NA · recruiting
NCT07417813 — A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders · recruiting
NCT06348082 — Project Women's Insomnia Sleep Health Equity Study (WISHES) · NA · recruiting

Other ProofPilot trials

Trials by the same sponsor.

NCT04914533 — Luminance RED for Canker Sores · NA · withdrawn
NCT04751864 — Brain Stimulation & Generalized Anxiety Study · Phase 4 · active not recruiting
NCT04541563 — Fisher Wallace Neurostimulation & Depression Study · NA · active not recruiting
NCT04471896 — Joovvin' for Your Skin Health Study · NA · completed
NCT04245254 — GutMe!: IBS and Collagen Protein Powder an Interventional Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04627480 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ProofPilot
Last refreshed: 14 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04627480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing